- Supported exchanges /
- F /
- 260.F
CENTESSA PHARMACEUTICALS (260 F) stock market data APIs
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.
CENTESSA PHARMACEUTICALS Financial Data Overview
| 13.7 | |
| 13.8 | |
| - | |
| 13.8 | |
| 13.7 | |
| 5.2-14.9 | |
| 1 804 M | |
| 129 M | |
| 6 853 K | |
| -0.65 | |
| 1.469 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
CENTESSA PHARMACEUTICALS Fundamental Data is available in our Financial Data APIs
- Net Revenue 6 853 K
- EBITDA -155 099 008
- Earnings Per Share -1.43
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get CENTESSA PHARMACEUTICALS Earnings via APIs
- Latest Release 2021-06-30
- EPS/Forecast -0.66
Get CENTESSA PHARMACEUTICALS End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
